Baseline | P values | 3 months,n=29;Renal, n=23 | 6 months,n=25;Renal, n=21 | 12 months,n=20;Renal, n=16 | |
SLEDAI (median±IQR) | 8 (5.5–12) | <0.001 | 4 (2–6) | 4 (2–6.5) | 3 (2–8) |
C3 (median, IQR) mg/dL | 74 (61–-3) | 0.02 | 81 (71–95) | 83 (72–99) | 84 (79–95) |
Renal subgroup | 65 (55–74) | 0.01 | 79 (69–88) | 81 (71–90) | 83 (77–92) |
Extrarenal subgroup | 78 (62–85) | 0.03 | 85 (78–95) | 86 (80–99) | 86 (81–99) |
Anti-ds DNA (%) | 75% | 0.02 | 70% | 58% | 25% |
Renal subgroup | 82% | 0.02 | 75% | 60% | 30% |
Extrarenal subgroup | 68% | 0.04 | 68% | 50% | 20% |
Creatinine mg/dl (median±IQR) | 0.7 (0.5–0.88) | n.s. | 0.82 (0.6–1.1) | 0.9 (0.6–1.17) | 0.8 (0.6–1.07) |
24 hours proteinuria mg (median±IQR) | 1425 (710–2630) | <0.001 | 530 (135–1250) | 350 (110–1000) | 380 (140–1500) |
PJ partial improvement (%) | 21 (75%) | 15 (71%) | 16 (94%) | ||
PJ complete resolution (%) | 9 (32%) | 8 (38%) | 10 (58%) | ||
Renal response, N (%) | 15 (65.2%) | 16 (76%) | 14 (87.5%) | ||
Renal complete response, N (%) | 8 (34%) | 9 (47%) | 8 (50%) |
PJ, physician’s judgement.